CB

Chengdu Brilliant Pharmaceutical at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Chengdu Brilliant Pharmaceutical brings 2 presentations to ObesityWeek 2026 in National Harbor. Its program centers on preclinical obesity drug candidates, including BPR-35000858, an ALK7-targeting siRNA that reduces adiposity with a favorable safety profile in mice and nonhuman primates. A poster covers a biased GLP-1 and amylin receptor dual agonist with a once-monthly formulation in obese rats.

OrganizationObesityWeek 2026 Attendance
CB
Chengdu Brilliant Pharmaceutical
Chengdu, China
Biotech
Drug developer with preclinical obesity programs, including an ALK7-targeting siRNA and a GLP-1/amylin dual agonist.
Talk
Sat Nov 14
3:45pm–4:00pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Chengdu Brilliant Pharmaceutical

Tell us what you sell and we’ll find the people at Chengdu Brilliant Pharmaceutical most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction